USFDA inspection at Tanuku facility ends with 6 observations in Form 483
WANBURY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts less than Nifty Microcap 250 and 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
USFDA completed a routine cGMP inspection at Wanbury's Tanuku facility in Andhra Pradesh from July 13 to July 17, 2026. The inspection ended with a Form 483 containing six observations. The company will respond within the stipulated time and says all observations are addressable. Wanbury expects no impact on manufacturing, US exports, or financial performance.
Form 483 observations are typically addressable; company expects no material impact on operations or finances, though USFDA follow-up remains a watch point.